Six-week immersive program featuring eight founders concludes with a Generative AI Summit PHILADELPHIA–(BUSINESS WIRE)–Today, Comcast…
Washington, DC-based REQ will support THP’s vision to rapidly scale through strategic investments to create…
Long-standing shareholders to receive a 10% bonus LYON, France & MIDDLETON, Wis.–(BUSINESS WIRE)–Esker, a global…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases a report on U.S. commercial mortgage-backed securities (CMBS) loan performance trends…
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical…
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
– U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic…
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient…
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend…
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all…
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies…
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…